A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of an Adeno-associated Virus Vector VV-14295 In Adults with Geographic Atrophy Secondary to Age-related Macular Degeneration